Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

By G. Phan, Jie Yang, R. Sherry, P. Hwu, S. Topalian, D. Schwartzentruber, N. Restifo, Leah R. Haworth, C. Seipp, Linda J Freezer and 7 more. Proceedings of the National Academy of Sciences of the United States of America, 2003

1,627 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/2491aece7923d300a5c1d9087a8c2e1f5fcb0513

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self (2005, background): “For example, administration of monoclonal antibody to CTLA-4 or to GITR, either of which can cause autoimmune disease in mice, is able to elicit effective tumor immunity by both attenuating T reg cell–mediated control of effector T cells and enhancing their effector activit”
Dendritic cell immunotherapy: mapping the way (2004, background): “In similar strategies, antibodies to CTLA-4 have been shown to block regulatory T cell”
Immunosuppressive networks in the tumour environment and their therapeutic relevance (2005, background): “The human anti-CTLA4 antibody (MDX-010) in conjunction with peptide vaccination improved tumour immunity and tumour regression in patients with metastatic melanom”
The blockade of immune checkpoints in cancer immunotherapy (2012, background): “Both antibodies produced objective clinical responses in ∼10% of patients with melanoma, but immune-related toxicities involving various tissue sites were also observed in 25–30% of patients, with colitis being a particularly common even”
Non-small cell lung cancer: current treatment and future advances. (2016, background): “Ipilimumab therapy in patients previously treated for metastatic melanoma demonstrated improved overall survival (84).”
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007, neutral): “0001 1-2 25 25 0 (0%) 3-4 25 23 2 (8%) 5-6 23 17 6 (26%) 7-8 7 3 4 (57%) >8 5 1 4 (80%) Total dosex (mg/kg) Median (range) 28 (3-70) 23 (3-70) 35.”
CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation (2017, background): “The discovery of immune checkpoint receptors, such as CTLA-4 and PD-1 (5-9), that repress the activity of anti-tumor T cells, led to the development of blocking antibodies directed against these co-inhibitory receptors or their ligands, including ipilimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), ”